Log in

NASDAQ:ZYNEZynerba Pharmaceuticals News Headlines

$3.50
-0.21 (-5.66 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.40
Now: $3.50
$3.69
50-Day Range
$3.37
MA: $5.42
$6.54
52-Week Range
$2.55
Now: $3.50
$15.70
Volume2.86 million shs
Average Volume3.23 million shs
Market Capitalization$87.33 million
P/E RatioN/A
Dividend YieldN/A
Beta3.09

Headlines

Zynerba Pharmaceuticals (NASDAQ ZYNE) News Headlines

Source:
DateHeadline
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Stock Rating Reaffirmed by HC WainwrightZynerba Pharmaceuticals (NASDAQ:ZYNE) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - July 2 at 11:43 AM
Zynerbas Zygel Fails in Phase III Fragile X Syndrome StudyZynerba's Zygel Fails in Phase III Fragile X Syndrome Study
www.nasdaq.com - July 1 at 2:21 PM
Zynerba's Zygel Fails in Phase III Fragile X Syndrome StudyZynerba's Zygel Fails in Phase III Fragile X Syndrome Study
finance.yahoo.com - July 1 at 2:21 PM
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Price Target Lowered to $8.00 at Cantor FitzgeraldZynerba Pharmaceuticals (NASDAQ:ZYNE) Price Target Lowered to $8.00 at Cantor Fitzgerald
www.americanbankingnews.com - July 1 at 10:40 AM
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Rating Lowered to Hold at Needham & Company LLCZynerba Pharmaceuticals (NASDAQ:ZYNE) Rating Lowered to Hold at Needham & Company LLC
www.americanbankingnews.com - July 1 at 10:40 AM
Canaccord Genuity Trims Zynerba Pharmaceuticals (NASDAQ:ZYNE) Target Price to $12.00Canaccord Genuity Trims Zynerba Pharmaceuticals (NASDAQ:ZYNE) Target Price to $12.00
www.americanbankingnews.com - July 1 at 9:27 AM
BRIEF-Zynerba Pharmaceuticals Announces Top Line Results From Pivotal Connect-FX Trial Of ZygelBRIEF-Zynerba Pharmaceuticals Announces Top Line Results From Pivotal Connect-FX Trial Of Zygel
www.reuters.com - June 30 at 11:38 PM
Synthetic Cannabinoid Drug Maker Zynerba Plummets 50%Synthetic Cannabinoid Drug Maker Zynerba Plummets 50%
www.benzinga.com - June 30 at 8:32 PM
Zynerba Cannabinoid Investors Must Now Refocus on Treating AutismZynerba Cannabinoid Investors Must Now Refocus on Treating Autism
www.msn.com - June 30 at 6:38 PM
Zynerbas Zygel flunks Fragile X studyZynerba's Zygel flunks Fragile X study
seekingalpha.com - June 30 at 8:37 AM
Zynerba Pharma: Zygel Study Fails To Achieve Statistical Significance In EndpointsZynerba Pharma: Zygel Study Fails To Achieve Statistical Significance In Endpoints
www.nasdaq.com - June 30 at 8:37 AM
Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X SyndromeZynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome
finance.yahoo.com - June 30 at 8:37 AM
Zynerba's cannabis-based drug for rare genetic disorder fails studyZynerba's cannabis-based drug for rare genetic disorder fails study
finance.yahoo.com - June 30 at 8:37 AM
Stock Traders Buy High Volume of Put Options on Zynerba Pharmaceuticals (NASDAQ:ZYNE)Stock Traders Buy High Volume of Put Options on Zynerba Pharmaceuticals (NASDAQ:ZYNE)
www.americanbankingnews.com - June 30 at 6:58 AM
Stock Traders Purchase Large Volume of Call Options on Zynerba Pharmaceuticals (NASDAQ:ZYNE)Stock Traders Purchase Large Volume of Call Options on Zynerba Pharmaceuticals (NASDAQ:ZYNE)
www.americanbankingnews.com - June 30 at 2:38 AM
Notable Monday Option Activity: ZYNE, RH, BBBYNotable Monday Option Activity: ZYNE, RH, BBBY
www.nasdaq.com - June 29 at 6:02 PM
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earns "Buy" Rating from LADENBURG THALM/SH SHZynerba Pharmaceuticals (NASDAQ:ZYNE) Earns "Buy" Rating from LADENBURG THALM/SH SH
www.americanbankingnews.com - June 29 at 9:30 AM
-$0.46 EPS Expected for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) This Quarter-$0.46 EPS Expected for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) This Quarter
www.americanbankingnews.com - June 26 at 9:02 PM
Zynerba Pharmaceuticals IncZynerba Pharmaceuticals Inc
www.bloomberg.com - June 21 at 10:12 PM
Traders Purchase Large Volume of Put Options on Zynerba Pharmaceuticals (NASDAQ:ZYNE)Traders Purchase Large Volume of Put Options on Zynerba Pharmaceuticals (NASDAQ:ZYNE)
www.americanbankingnews.com - June 16 at 6:59 AM
Zynerba Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ZYNE)Zynerba Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ZYNE)
www.americanbankingnews.com - June 15 at 3:41 PM
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Given Consensus Recommendation of "Buy" by BrokeragesZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 13 at 8:52 AM
Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock OptionsImplied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
www.nasdaq.com - May 28 at 12:49 PM
Zynerbas ZYN002 shows positive action in autism studyZynerba's ZYN002 shows positive action in autism study
seekingalpha.com - May 27 at 11:46 AM
BRIEF-Zynerba Says Bright Trial Achieved Clinically Meaningful Improvements From BaselineBRIEF-Zynerba Says Bright Trial Achieved Clinically Meaningful Improvements From Baseline
www.reuters.com - May 27 at 11:46 AM
Main Line pharma company reports exciting step forward with experimental autism treatmentMain Line pharma company reports 'exciting step forward' with experimental autism treatment
www.bizjournals.com - May 27 at 11:46 AM
Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum DisorderZynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
finance.yahoo.com - May 27 at 11:46 AM
BRIEF-Zynerba Pharmaceuticals Announces New Two-Year Data From Open Label Extension Of The Phase 2 Fab-C Trial In Patients With Fragile XBRIEF-Zynerba Pharmaceuticals Announces New Two-Year Data From Open Label Extension Of The Phase 2 Fab-C Trial In Patients With Fragile X
www.reuters.com - May 26 at 12:41 PM
Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual SessionZynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session
finance.yahoo.com - May 26 at 7:36 AM
Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual SessionZynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session
finance.yahoo.com - May 26 at 7:36 AM
Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferenceZynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 22 at 7:38 AM
Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 PandemicZynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic
finance.yahoo.com - May 21 at 12:46 PM
BRIEF-Zynerba Pharmaceuticals Reports First Quarter 2020 ResultsBRIEF-Zynerba Pharmaceuticals Reports First Quarter 2020 Results
www.reuters.com - May 11 at 9:22 PM
Zynerba up 23% ahead of key data readoutsZynerba up 23% ahead of key data readouts
seekingalpha.com - May 11 at 4:21 PM
Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
finance.yahoo.com - May 11 at 8:33 AM
How Much is Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) CEO Getting Paid?How Much is Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) CEO Getting Paid?
finance.yahoo.com - April 28 at 1:39 PM
INVESTOR ALERT - Zynerba Pharmaceuticals, Inc. (ZYNE) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class ActionINVESTOR ALERT - Zynerba Pharmaceuticals, Inc. (ZYNE) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action
www.bloomberg.com - April 24 at 5:48 PM
Medical CBD Company Zynerba Rallies On Q4 Report, CEO Says 2020 Outlook PromisingMedical CBD Company Zynerba Rallies On Q4 Report, CEO Says 2020 Outlook 'Promising'
www.benzinga.com - March 10 at 2:00 PM
Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
www.globenewswire.com - March 10 at 8:59 AM
Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
finance.yahoo.com - March 10 at 8:59 AM
Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual MeetingZynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting
finance.yahoo.com - March 9 at 1:05 PM
Zynerba Pharmaceuticals to Present at the 32nd Annual ROTH ConferenceZynerba Pharmaceuticals to Present at the 32nd Annual ROTH Conference
finance.yahoo.com - March 5 at 11:42 AM
Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers 
finance.yahoo.com - March 3 at 12:44 PM
Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study PopulationZynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population
finance.yahoo.com - March 3 at 12:44 PM
BRIEF-Zynerba Pharmaceuticals Announces The Completion Of Enrollment In The Pivotal Connect-FX Trial Of Zygel In Fragile X SyndromeBRIEF-Zynerba Pharmaceuticals Announces The Completion Of Enrollment In The Pivotal Connect-FX Trial Of Zygel In Fragile X Syndrome
www.reuters.com - February 26 at 2:57 PM
Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X SyndromeZynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome
finance.yahoo.com - February 26 at 8:03 AM
Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) Path To ProfitabilityZynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) Path To Profitability
finance.yahoo.com - February 25 at 2:10 PM
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified CannabidiolZynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified Cannabidiol
finance.yahoo.com - February 25 at 7:37 AM
Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual MeetingZynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual Meeting
finance.yahoo.com - February 20 at 8:35 AM
Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should KnowZynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know
finance.yahoo.com - February 10 at 7:26 PM
This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.